Human Alpha-Fetoprotein (AFP) recombinant, non-glycosylated AFP is a human protein produced by the embryo during fetal development and serves at least two critical functions:

1. Picks up nutrients from the mother and delivers them to the embryo;
2. Is thought to normalizes the immune system responses so the mother’s immune cells don’t attack the embryo.

AFP circulates in the maternal bloodstream and picks up free fatty acids, steroids, and other hydrophobic substances, needed by rapidly dividing cells. The loaded AFP continues to circulate until it finds receptors which are exclusively found on all embryonic cells. It then transports the nutrients into the cell and releases them once inside. When the embryo matures the production of AFP stops and the receptors disappear. Cancer cells in many ways can be viewed as reverting to an embryonic state and > 80% of solid and liquid tumors (leukemia, lymphoma) express AFP receptors on their surface while healthy cells do not. By attaching a chemotherapy payload to AFP we can selectively deliver toxins to cancer cells. This targeted delivery prevents chemotherapy from entering healthy cells resulting in increased efficacy and a significant reduction in toxicity. It is well known that symptoms of autoimmune diseases (Multiple Sclerosis, Myasthenia Gravis, Lupus, Arthritis etc.) go into remission during pregnancy and return soon after. This seems to correlates very well with the rise and fall of AFP. In various pre-clinical models of autoimmune diseases administration of AFP is a very effective therapy. ACT has exclusive worldwide rights to recombinant human alpha fetoprotein (rHuAFP).